Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Iloprost trometamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Ventavis is The active substance of Ventavis is iloprost. It imitates a natural substance in the body called prostacyclin. Ventavis inhibits unwanted blocking or narrowing of blood vessels and allows more blood to flow through the vessels. What Ventavis is used for Ventavis is used to treat moderate cases of primary pulmonary hypertension (PPH) in adult patients. PPH is a category of pulmonary hypertension where the cause of the high blood pressure is not known. This is a condition where blood pressure is too high in the blood vessels between the heart and the lungs. Ventavis is used to improve exercise capacity (the ability to carry out physical activity) and symptoms. How Ventavis works Breathing in the mist carries Ventavis to the lungs, where it can work most effectively in the artery between heart and lungs. Improved blood flow leads to a better supply of oxygen to the body and reduced strain on the heart. 2.
e Ventavis
Do not use Ventavis
GB v003_0
Page 1 of 10
–
• •
poor blood flow to the heart muscles (severe coronary heart disease or unstable angina). Symptoms can include chest pain,
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Ventavis: •
• •
• •
• •
Inhaling Ventavis might trigger breathing difficulties (see section 4), especially in patients with bronchospasm (sudden constriction of the muscles in the walls of the small airways) and wheezing. Tell your doctor if you have a lung infection, severe asthma, or chronic lung disease (chronic obstructive pulmonary disease). Your doctor will monitor you closely. Your blood pressure will be checked before treatment and if it is too low (less than 85 mmHg for the upper value) then therapy with Ventavis should not be started. In general, you will need to take special care to try and avoid effects of low blood pressure, such as fainting and dizziness: Tell your doctor if you are taking any other medication because the combined effect with Ventavis may lower your blood pressure further (see below "Other medicines and Ventavis"). Stand up slowly when you get out of chairs or bed. If you tend to faint as soon as you get out of bed, it may be helpful to take your first dose of the day while you are still lying down. If you tend to experience fainting episodes, avoid any exceptional straining, for example during physical exertion; it might be useful to inhale Ventavis before. Fainting episodes may be due to the underlying disease. Tell your doctor if they get worse. He/she may consider adjusting your dose or changing your treatment. If you suffer from a weak heart condition such as right heart failure, and feel that your disease is worsening, tell your doctor. Symptoms can include swelling of feet and ankles, shortness of breath, palpitations, urinating more frequently at night or oedema. Your doctor will consider changing your treatment. If you experience difficulty breathing, cough up blood, and/or sweat excessively these may be signs that you have water in the lungs (lung oedema). Stop using Ventavis and tell your doctor immediately. He/she will look for the cause and take appropriate measures. If you have liver problems or very severe kidney problems, requiring dialysis, tell your doctor. You may be gradually introduced to the prescribed dose or be prescribed a lower dose of Ventavis than for other patients (see section 3. "How to use Ventavis").
Contact of Ventavis with skin or swallowing Ventavis • Do NOT let Ventavis solution come into contact with your skin or eyes. If it does, rinse the skin or your eyes immediately with plenty of water. • Do NOT drink or swallow Ventavis solution. If you swallow it accidentally, drink plenty of water and tell your doctor. Children and adolescents The safety and efficacy of Ventavis in children aged up to 18 years have not been established.
GB v003_0
Page 2 of 10
Other medicines and Ventavis Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. Ventavis and certain other medicines may affect each other in the way they work in your body. Tell your doctor if you are taking: Medicines used to treat high blood pressure or heart disease, such as beta blockers, nitro-vasodilators, ACE inhibitors. Your blood pressure may drop much further. Your doctor may change the dosage. •
•
Medicines that thin the blood or inhibit blood clotting, this includes
Before taking any medicine ask your doctor or pharmacist, who has more information on medicines to be careful with or avoid when using Ventavis. Ventavis with food and drink Food or drink is not expected to affect Ventavis. However, you should avoid taking food or drink during inhalation. Pregnancy
GB v003_0
Page 3 of 10
Driving and using machines Ventavis lowers blood pressure and may cause dizziness or light-headedness in some people. Do not drive or operate any tools or machines if you feel these effects. Ventavis contains ethanol Ventavis 20 microgram/ml contains 1.62 mg alcohol (ethanol) in each ml which is equivalent to 0.162% (w/v). The amount of 1.62 mg of alcohol in 1 ml of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects. 3.
Ventavis
Ventavis therapy should only be initiated by a physician experienced in treatment of pulmonary hypertension. How much to inhale and for how long Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The dose of Ventavis and the duration of treatment that is right for you depend on your individual condition. Your doctor will advise you. Do not change the recommended dose without consulting your doctor first. Different nebuliser devices can be used to administer Ventavis 20μg/ml. •
Breelib nebuliser
If you are starting Ventavis treatment or if you switch from an alternative device your first inhalation will be with Ventavis 10 microgram/ml (1 ml ampoule with white and yellow rings). If you tolerate this dose well, your next inhalation will be with Ventavis 20 microgram/ml (ampoule with yellow and red rings). You should continue on this dose. If you cannot tolerate inhalation of Ventavis 20 microgram/ml talk to your doctor who may decide that you should take Ventavis 10 microgram/ml (1 ml ampoule). Most people will have 6 to 9 inhalation sessions spread throughout the day. One inhalation session with Breelib will usually last about 3 minutes. Your doctor will supervise your treatment when you start using the Breelib nebuliser to ensure that you tolerate dose and speed of inhalation well. •
I-Neb nebuliser
As you repeatedly experience extended inhalation treatment times with Ventavis 10 microgram/ml (1 ml ampoule with white and yellow rings), your doctor decided to switch to Ventavis 20 microgram/ml. Ventavis 20 microgram/ml is double the concentration of Ventavis 10 microgram/ml. The active substance can be delivered more rapidly to your lungs. Your doctor will supervise your treatment if switching from Ventavis 10 microgram /ml to Ventavis 20 microgram/ml to monitor how well you tolerate the higher concentration. You should administer the dose 6 to 9 times per day according to individual needs and tolerability. Depending on your individual needs, Ventavis can be used for long term treatment.
GB v003_0
Page 4 of 10
If you have kidney or liver problems There is no need to alter the dose in patients with mild or moderate kidney problems (patients with a creatinine clearance >30 ml/min). If you have very severe kidney problems and require dialysis or if you have liver problems, your doctor will introduce you to Ventavis gradually and possibly prescribe fewer daily inhalations. Start therapy by inhaling 2.5 microgram iloprost using Ventavis 10 micrograms/ml (1 ml ampoule with white and yellow rings). Use dosing intervals of 3 – 4 hours (this corresponds to a maximum of 6 administrations per day). Thereafter, your doctor may cautiously shorten the dosing intervals depending on how you tolerate the treatment. If your doctor decides to further increase the dose up to 5 microgram, again dosing intervals of 3 – 4 hours should be chosen initially and shortened depending on how you tolerate the treatment. If you feel that the effect of Ventavis is too strong or too weak, talk to your doctor or pharmacist. Ask your doctor to have someone help you become thoroughly familiar with the use of the nebuliser. You should not switch to another nebuliser without consulting the doctor who is treating you. How to inhale For each inhalation session you should use a new ampoule of Ventavis. Just before you start to inhale, break the glass ampoule and pour the solution into the medication chamber following the instructions for use of the nebuliser. Follow carefully the instructions that come with the nebuliser especially the instructions on hygiene and cleaning of the nebuliser. Always take Ventavis exactly as your doctor has told you. • Ventavis 20 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib or the I-Neb AAD nebuliser). • The nebuliser turns Ventavis solution into a mist which you breathe in through your mouth. • For the inhalation you should use a mouthpiece to prevent Ventavis coming into contact with your skin. Do not use a facial mask. • Follow carefully any instructions that come with the nebuliser. Check with your doctor or pharmacist if you are unsure. • Any Ventavis solution remaining in the nebuliser after inhalation must be thrown away (see section 5). Room ventilation Be sure to ventilate or air the room in which you have taken your Ventavis treatment. Other people might accidentally be exposed to Ventavis through the room air. In particular, newborns, infants and pregnant women should not be in the same room while you are inhaling Ventavis. •
Breelib
Fill the medication chamber with Ventavis immediately before use. For filling please follow the instructions for use of the nebuliser. Device
Drug product
Dose of iloprost at mouthpiece
Estimated inhalation time
Breelib
Ventavis 20 mcg/ml (1 ml ampoule with yellow and red rings)
5 mcg
3 minutes
GB v003_0
Page 5 of 10
I-Neb AAD 1. Just before you start to inhale, take the yellow-red colour coded ampoule of Ventavis 20 microgram/ml, break the glass ampoule and pour the complete contents of 1 ml into the nebuliser medication golden chamber. 2. The pre-set dose provided by the I-Neb AAD nebuliser is controlled by the medication chamber in combination with a control disc. For Ventavis 20 microgram/ml (5 microgram dose), the medication chamber with the golden coloured latch is used together with the golden control disc. 3. To ensure that you receive the prescribed dose, check the colour of the medication chamber and the colour of the control disc. They should both have the same colour. Since the I-Neb AAD nebuliser can be used for Ventavis 10 microgram/ml and Ventavis 20 microgram/ml, the table below provides a summary of the user instructions of the I-Neb for the 2 concentrations of Ventavis: Drug product
Ampoule / coloured rings
Ventavis 10 mcg/ml
1 ml ampoule white-yellow ring
Ventavis 20 mcg/ml
1 ml ampoule yellow-red ring
Dosage 2.5 mcg 5 mcg 5 mcg
I-Neb AAD Medication Control disc chamber latch red
red
purple
purple
golden
golden
For further details please refer to the instruction manual of the nebuliser device or ask your doctor.
If you use more Ventavis than you should Using more Ventavis than you should may lead to dizziness, headache, flushing (reddening of the face), nausea (feeling sick), jaw pain or back pain. You may also experience a decrease or an increase in blood pressure, bradycardia (reduced heart rate), tachycardia (increased heart rate), vomiting, diarrhoea or limb pain. If any of these happen when you have used more Ventavis than you should:
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following serious side effects may occur. In this case talk to your doctor immediately.
GB v003_0
Page 6 of 10
Very common (may affect more than 1 in 10 people): Bleeding events (mostly nosebleed (epistaxis) and coughing up blood (haemoptysis) may very commonly occur, especially if you are also taking blood-thinning medicines (anticoagulants). The risk of bleeding may be increased in patients when inhibitors of platelet aggregation or anticoagulants are given at the same time (see also section 2). Very rarely, fatal cases including bleeding in the brain
(cerebral and intracranial haemorrhage) have been reported.
Common (may affect up to 1 in 10 people):
GB v003_0
Page 7 of 10
Reporting of side effects If you get any side effects talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5.
Ventavis
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and ampoule. This medicine does not require any special storage conditions. Any Ventavis solution remaining in the nebuliser must be thrown away. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Ventavis contains: • The active substance is iloprost. 1 ml solution contains 20 microgram iloprost (as iloprost trometamol). Each ampoule with 1 ml contains 20 microgram iloprost. • The other ingredients are trometamol, ethanol, sodium chloride, hydrochloric acid for pH adjustment, and water for injections. What Ventavis looks like and content of the pack: Ventavis is a clear, colourless to slightly yellowish nebuliser solution for inhalation with the Breelib or the I-Neb nebuliser. Ventavis 20 microgram/ml is provided in colourless ampoules, containing 1 ml nebuliser solution. Ventavis 20 microgram/ml is available in the following packs: Pack containing 30 ampoules or 42 ampoules for use with the Breelib and I-Neb nebuliser. Multipack containing 168 (4×42) ampoules for use with the Breelib and I-Neb nebuliser. Multipack containing 168 (4×42) ampoules with Breelib consumables set (containing 1 mouthpiece and 1 medication chamber). The ampoules containing 1 ml are marked with two coloured rings (yellow-red). Not all pack-sizes may be marketed. Marketing Authorisation Holder: Bayer plc 400 South Oak Way Reading RG2 6AD Manufacturer: Berlimed S.A. Francisco Alonso 7 Polígono Industrial Santa Rosa GB v003_0
Page 8 of 10
28806 Alcala de Henares Madrid Spain For any information about this medicine, please contact the Marketing Authorisation Holder. Bayer plc Tel: +44 (0)118 206 3000 This leaflet was last revised in 07/2024.
The following information is intended for healthcare professionals only: Instructions for use and handling Patients stabilised on one nebuliser should not switch to another nebuliser without close supervision by the treating doctor as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and may have faster delivery of the solution (see section 5.2 of the Summary of Product Characteristics). To minimise accidental exposure, it is recommended to keep the room well ventilated. •
Breelib
When using the Breelib nebuliser please follow the instructions for use provided with the device. Fill the medication chamber with Ventavis immediately before use. Dose of iloprost at Device
Drug product
mouthpiece
Estimated inhalation time
Breelib
Ventavis 20 mcg/ml (1 ml ampoule with yellow and red rings)
5 mcg
3 minutes
•
I-Neb AAD:
The I-Neb AAD System is a portable, hand-held, vibrating mesh technology nebuliser system. This system generates droplets by ultrasound, which is forcing the solution through a mesh. This nebuliser monitors the breathing pattern to determine the aerosol pulse time required to deliver the pre-set dose of 5 micrograms iloprost of the Ventavis 20 microgram/ml nebuliser solution (1 ml ampoule with yellow and red rings). The nebulising device delivers 5 microgram iloprost at the mouthpiece. The Mass Median Aerodynamic Diameter (MMAD) of the aerosol is between 1 and 5 micrometers. When using the I-Neb AAD system the following instructions need to be followed. The dose delivered by the I-Neb AAD system is controlled by the medication chamber in combination with a control disc. For each medication chamber there is a corresponding colour coded control disc. For each inhalation session with the I-Neb AAD, the content of one 1-ml ampoule of Ventavis 20 microgram/ml, showing two coloured rings (-yellow-red), will be transferred into the appropriate nebuliser medication chamber with golden coloured latch together with the golden colour disc immediately before use. GB v003_0
Page 9 of 10
Since the I-Neb AAD system can be used for Ventavis 10 microgram/ml and Ventavis 20 microgram/ ml, the table below provides a summary of the user instructions of the I-Neb for the 2 concentrations of Ventavis: Drug product
Ampoule / coloured rings
Ventavis 10 mcg/ml
1 ml ampoule white-yellow ring
Ventavis 20 mcg/ml
1 ml ampoule yellow-red ring
Dosage 2.5 mcg 5 mcg 5 mcg
I-Neb AAD Medication Control disc chamber latch red
red
purple
purple
golden
golden
The efficacy and tolerability of inhaled iloprost when administered with other nebulising systems, which provide different nebulisation characteristics of iloprost solution, have not been established.
GB v003_0
Page 10 of 10
Ventavis 20 microgram/ml nebuliser solution comes as inhaler containing 20microgram/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Ventavis 20 microgram/ml nebuliser solution is iloprost trometamol.
This leaflet reproduces the patient information leaflet approved for Ventavis 20 microgram/ml nebuliser solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of adult patients with primary pulmonary hypertension, classified as NYHA functional class III, to improve exercise capacity and symptoms.
Drug product
Suitable inhalation device (nebuliser) to be used
Ventavis 20 microgram/ml
Breelib
I-Neb AAD
Ventavis should only be initiated and monitored by a physician experienced in the treatment of pulmonary hypertension.
Posology
Dose per inhalation session
At initiation of Ventavis treatment the first inhaled dose should be 2.5 microgram iloprost as delivered at the mouthpiece of the nebuliser. If this dose is well tolerated, dosing should be increased to 5 microgram iloprost and maintained at that dose. In case of poor tolerability of the 5 microgram dose, the dose should be reduced to 2.5 microgram iloprost.
Daily dose
The dose per inhalation session should be administered 6 to 9 times per day according to the individual need and tolerability.
Duration of treatment
The duration of treatment depends on clinical status and is left to the physician's discretion. Should patients deteriorate on this treatment intravenous prostacyclin treatment should be considered.
Special populations
Hepatic impairment
Iloprost elimination is reduced in patients with hepatic dysfunction (see section 5.2).
To avoid undesired accumulation over the day, special caution has to be exercised with these patients during initial dose titration. Initially, doses of 2.5 microgram iloprost should be administered using Ventavis 10 microgram/ml with dosing intervals of 3-4 hours (corresponds to administration of max. 6 times per day). Thereafter, dosing intervals may be shortened cautiously based on individual tolerability. If a dose up to 5 microgram iloprost is indicated, again dosing intervals of 3-4 hours should be chosen initially and shortened according to individual tolerability. An accumulation of iloprost following treatment over several days is not likely due to the overnight break in administration of the medicinal product.
Renal impairment
There is no need for dose adaptation in patients with a creatinine clearance >30 ml/min (as determined from serum creatinine using the Cockroft and Gault formula). Patients with a creatinine clearance of ≤30 ml/min were not investigated in the clinical trials. Data with intravenously administered iloprost indicated that the elimination is reduced in patients with renal failure requiring dialysis. Therefore, the same dosing recommendations as in patients with hepatic impairment (see above) are to be applied.
Paediatric population
The safety and efficacy of Ventavis in children aged up to 18 years have not been established.
No data from controlled clinical trials are available.
Method of administration
Ventavis is intended for inhalation use by nebulisation.
To minimize accidental exposure it is recommended to keep the room well ventilated.
The ready-to-use Ventavis nebuliser solution is administered with a suitable inhalation device (nebuliser) (see below and section 6.6).
Patients stabilised on one nebuliser should not switch to another nebuliser without supervision by the treating physician as different nebulisers have been shown to produce aerosols with slightly different physical characteristics and delivery of the solution that may be faster (see section 5.2).
• Breelib
Breelib is a small handheld, battery-powered, breath activated, vibrating mesh technology system.
Ventavis 10 microgram/ml (1 ml ampoule) and Ventavis 20 microgram/ml nebuliser solution
Ventavis 10 microgram/ml nebuliser solution (1 ml ampoule) delivers 2.5 microgram and Ventavis 20 microgram/ml nebuliser solution delivers 5 microgram at the mouthpiece of the Breelib nebuliser.
At initiation of Ventavis treatment or if the patient is switched from an alternative device, the first inhalation should be made with 1 ml ampoule of Ventavis 10 microgram/ml (see section 4.4). If inhalation with Ventavis 10 microgram/ml is well tolerated, the dose should be increased by using Ventavis 20 microgram/ml. This dose should be maintained. In case of poor tolerability of Ventavis 20 microgram/ml, the dose should be reduced by using 1 ml ampoule of Ventavis 10 microgram/ml (see section 4.4).
The duration of an inhalation session with Breelib nebuliser is approximately 3 minutes, which reflects the higher delivery rate of the Breelib compared to other nebulisers.
Patients initiating Ventavis treatment or switching from an alternative device to Breelib should be closely supervised by the treating physician to ensure that dose and speed of inhalation are well tolerated.
When using the Breelib nebuliser please follow the instructions for use provided with the device.
Fill the medication chamber with Ventavis immediately before use.
• I-Neb AAD
The I-Neb AAD system is a portable, hand-held, vibrating mesh technology nebuliser system. This system generates droplets by ultrasound, which forces the solution through a mesh. The I-Neb AAD nebuliser has been shown to be suitable for the administration of Ventavis 10 microgram/ml (1 ml ampoule) and 20 microgram/ml nebuliser solution. The Mass Median Aerodynamic Diameter (MMAD) of the aerosol measured using I-Neb nebulising systems equipped with power level 10 disc was similar between Ventavis 20 microgram/ml (golden programme) and Ventavis 10 microgram/ml (purple programme) nebuliser solutions (i.e.: around 2 micrometres) but with faster delivery when using Ventavis 20 microgram/ml.
The dose delivered by the I-Neb AAD system is controlled by the medication chamber in combination with a control disc. Each medication chamber is colour coded and has a corresponding colour coded control disc.
Ventavis 20 microgram/ml nebuliser solution
Only patients who are maintained at the 5 microgram dose and who have repeatedly experienced extended inhalation times with Ventavis 10 microgram/ml, which could result in incomplete inhalation, may be considered suitable for switching to Ventavis 20 microgram/ml.
Close supervision by the treating physician is necessary if switching from Ventavis 10 microgram/ml to Ventavis 20 microgram/ml to control the acute tolerance relating to faster delivery rate of iloprost with the double concentration.
This nebuliser monitors the breathing pattern to determine the aerosol pulse time required to deliver the pre-set dose of 5 microgram iloprost.
For the 5 microgram dose of Ventavis 20 microgram/ml the medication chamber with the gold coloured latch is used together with the gold control disc.
For each inhalation session with the I-Neb AAD, the content of one 1 ml ampoule of Ventavis 20 microgram/ml with two coloured rings (yellow - red), is transferred into the medication chamber immediately before use.
Drug product
Ampoule coloured rings
Dosage
I-Neb AAD
Medication chamber latch
Control disc
Ventavis 20 mcg/ml
1 ml ampoule
yellow - red ring
5 mcg
golden
golden
Other nebulising systems
The efficacy and tolerability of inhaled iloprost when administered with other nebulising systems, which provide different nebulisation characteristics of iloprost solution, have not been established.
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Conditions where the effects of Ventavis on platelets might increase the risk of haemorrhage (e.g. active peptic ulcers, trauma, intracranial haemorrhage).
- Severe coronary heart disease or unstable angina.
- Myocardial infarction within the last six months.
- Decompensated cardiac failure if not under close medical supervision.
- Severe arrhythmias.
- Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months.
- Pulmonary hypertension due to venous occlusive disease.
- Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
The use of Ventavis is not recommended in patients with unstable pulmonary hypertension, with advanced right heart failure. In case of deterioration or worsening of right heart failure transfer to other medicinal products should be considered.
Hypotension
Blood pressure should be checked while initiating Ventavis. In patients with low systemic blood pressure and in patients with postural hypotension or receiving medicinal products known to reduce blood pressure levels, care should be taken to avoid further hypotension. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mmHg.
Physicians should be alerted to the presence of concomitant conditions or medicinal products that might increase the risk of hypotension and syncope (see section 4.5).
Syncope
The pulmonary vasodilatory effect of inhaled iloprost is of short duration (one to two hours).
Syncope is a common symptom of the disease itself and can also occur under therapy. Patients who experience syncope in association with pulmonary hypertension should avoid any exceptional straining, for example during physical exertion. Before physical exertion it might be useful to inhale. The increased occurrence of syncope can reflect therapeutic gaps, insufficient effectiveness and/or deterioration of the disease. The need to adapt and/or change the therapy should be considered (see section 4.8).
Patients with diseases of the respiratory tract
Ventavis inhalation might entail the risk of inducing bronchospasm, especially in patients with bronchial hyperactivity (see section 4.8). Moreover, the benefit of Ventavis has not been established in patients with concomitant Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. Patients with concomitant acute pulmonary infections, COPD and severe asthma should be carefully monitored.
Pulmonary veno-occlusive disease
Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease. Should signs of pulmonary oedema occur, the possibility of associated pulmonary veno-occlusive disease should be considered and treatment with Ventavis should be discontinued.
Interruption of therapy
In case of interruption of Ventavis therapy, the risk of rebound effect is not formally excluded. Careful monitoring of the patient should be performed, when inhaled iloprost therapy is stopped and an alternative treatment should be considered in critically ill patients.
Renal or hepatic impairment
Data with intravenously administered iloprost indicated that the elimination is reduced in patients with hepatic dysfunction and in patients with renal failure requiring dialysis (see section 5.2). A cautious initial dose titration using dosing intervals of 3-4 hours is recommended (see section 4.2).
Serum glucose levels
Prolonged oral treatment with iloprost clathrate in dogs up to one year was associated with slightly increased fasted serum glucose levels. It cannot be excluded that this is also relevant to humans on prolonged Ventavis therapy.
Undesirable exposure to Ventavis
To minimise accidental exposure, it is recommended to use Ventavis with nebulisers with inhalation-triggered systems (such Breelib or I-Neb), and to keep the room well ventilated.
Newborns, infants and pregnant women should not be subjected to Ventavis in the room air.
Skin and eye contact, oral ingestion
Ventavis nebuliser solution should not come into contact with skin and eyes; oral ingestion of Ventavis solution should be avoided. During nebulisation sessions a facial mask must be avoided and only a mouthpiece should be used.
Ventavis contains ethanol
Ventavis 20 microgram/ml contains 1.62 mg alcohol (ethanol) in each ml which is equivalent to 0.162% (w/v). The amount of 1.62 mg of alcohol in 1 ml of this medicine is equivalent to less than 1 ml beer or wine.
The small amount of alcohol in this medicine will not have any noticeable effects.
Switching to the Breelib nebuliser
Limited data are available on the use of the Breelib nebuliser. For patients being switched from an alternative device to the Breelib nebuliser the first inhalation should be made with Ventavis 10 microgram/ml (1ml ampoule) delivering 2.5 microgram iloprost at the mouthpiece and under close medical supervision to ensure that the faster inhalation provided by Breelib is well tolerated. First dosing with 2.5 microgram should be done even if patients had already been stable on 5 microgram inhaled with an alternative device (see section 4.2).
Iloprost may increase the effects of vasodilatators and antihypertensive agents and then favour the risk of hypotension (see section 4.4). Caution is recommended in case of co-administration of Ventavis with other antihypertensive or vasodilatating agents as dose adjustment might be required.
Since iloprost inhibits platelet function its use with the following substances may enhance iloprost-mediated platelet inhibition, thereby increasing the risk of bleeding:
• anticoagulants such as
- heparin,
- oral anticoagulants (either coumarin-type or direct)
• or other inhibitors of platelet aggregation, such as
- acetylsalicylic acid,
- non-steroidal anti-inflammatory medicinal products,
- non-selective phosphodiesterase inhibitors like pentoxifylline,
- selective phosphodiesterase 3 (PDE3) inhibitors like cilostazol or anagrelide
- ticlopidine,
- clopidogrel,
- glycoprotein IIb/IIIa antagonists, like:
o abciximab,
o eptifibatide
o tirofiban
o defibrotide.
A careful monitoring of the patients taking anticoagulants or other inhibitors of platelet aggregation according to common medical practice is recommended.
Intravenous infusion of iloprost has no effect either on the pharmacokinetics of multiple oral doses of digoxin or on the pharmacokinetics of co-administered tissue plasminogen activator (t-PA) in patients.
Although, clinical studies have not been conducted, in vitro studies investigating the inhibitory potential of iloprost on the activity of cytochrome P450 enzymes revealed that no relevant inhibition of drug metabolism via these enzymes by iloprost is to be expected.
Women of childbearing potential
Women of childbearing potential should use effective contraceptive measures during treatment with Ventavis.
Pregnancy
Women with pulmonary hypertension (PH) should avoid pregnancy as it may lead to life-threatening exacerbation of the disease.
Animal studies have shown reproductive effects (see section 5.3).
There is a limited amount of data from the use of iloprost in pregnant women. If a pregnancy occurs, taking into account the potential maternal benefit, the use of Ventavis during pregnancy may be considered, only following careful benefit-risk evaluation, in those women who choose to continue their pregnancy, despite the known risks of pulmonary hypertension during pregnancy.
Breast-feeding
It is not known whether iloprost/metabolites are excreted in human breast milk. Very low levels of iloprost into milk were observed in rats (see section 5.3). A potential risk to the breast-feeding child cannot be excluded and it is preferable to avoid breast-feeding during Ventavis therapy.
Fertility
Animal studies have not shown harmful effect of iloprost on fertility.
Ventavis has major influence on the ability to drive and use machines for patients experiencing hypotensive symptoms such as dizziness.
Care should be exercised during initiation of therapy until any effects on the individual have been determined.
Summary of the safety profile
In addition to local effects resulting from administration of iloprost by inhalation such as cough, adverse reactions with iloprost are related to the pharmacological properties of prostacyclins.
The most frequently observed adverse reactions (≥ 20 %) in clinical trials include vasodilatation (including hypotension), headache and cough. The most serious adverse reactions were hypotension, bleeding events, and bronchospasm.
Tabulated list of adverse reactions
The adverse reactions reported below are based on pooled clinical trial data from phase II and III clinical trials involving 131 patients taking the medicinal product and on data from post-marketing surveillance. The frequencies of adverse reactions are defined as very common (≥1/10) and common (≥1/100 to <1/10). The adverse reactions identified only during post-marketing surveillance, and for which a frequency could not be estimated from clinical trial data, are listed under "Frequency not known".
Within each frequency grouping, adverse reaction are presented in order of decreasing seriousness.
System organ class
(MedDRA)
Very common
(≥1/10)
Common
(≥1/100 to <1/10)
Not known (cannot be estimated from the available data)
Blood and lymphatic system disorders
Bleeding events*§
Thrombocytopenia
Immune system disorders
Hypersensitivity
Nervous system disorders
Headache
Dizziness
Cardiac disorders
Tachycardia, Palpitations
Vascular disorders
Vasodilatation Flushing
Syncope§ (see section 4.4)
Hypotension*
Respiratory, thoracic and mediastinal disorders
Chest discomfort / chest pain
Cough
Dyspnoea
Pharyngolaryngeal pain
Throat irritation
Bronchospasm* (see section 4.4) /
Wheezing
Gastrointestinal disorders
Nausea
Diarrhoea
Vomiting
Mouth and tongue irritation including pain
Dysgeusia
Skin and subcutaneous tissue disorders
Rash
Musculoskeletal and connective tissue disorders
Pain in jaw/trismus
General disorders and administration site condition
Peripheral oedema§
* Life-threatening and/or fatal cases have been reported.
§ see section “Description of selected adverse reactions”
Description of selected adverse reactions
Bleeding events (mostly epistaxis and haemoptysis) were very common as expected in this patient population with a high proportion of patients taking anticoagulant co-medication. The risk of bleeding may be increased in patients when potential inhibitors of platelet aggregation or anticoagulants are given concomitantly (see section 4.5). Fatal cases included cerebral and intracranial haemorrhage.
Syncope is a common symptom of the disease itself, but can also occur under therapy. The increased occurrence of syncope can be related to the deterioration of the disease or insufficient effectiveness of the product (see section 4.4).
In clinical trials peripheral oedema was reported in 12.2% of patients on iloprost and 16.2% of patients on placebo. Peripheral oedema is a very common symptom of the disease itself, but can also occur under therapy. The occurrence of peripheral oedema can be related to the deterioration of the disease or insufficient effectiveness of the product.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Cases of overdose were reported. Symptoms of overdoses are mainly related to the vasodilatory effect of iloprost. Frequently observed symptoms following overdose are dizziness, headache, flushing, nausea, jaw pain or back pain. Hypotension, an increase of blood pressure, bradycardia or tachycardia, vomiting, diarrhoea and limb pain might also be possible.
Management
A specific antidote is not known. Interruption of the inhalation session, monitoring and symptomatic measures are recommended.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Same active substance, but a different pharmaceutical form (for example a gel instead of a tablet). Not interchangeable — ask a pharmacist.
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Ventavis 20 microgram/ml nebuliser solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.